ATE233090T1 - Darifenacin enthaltende pharmazeutische zubereitungen - Google Patents

Darifenacin enthaltende pharmazeutische zubereitungen

Info

Publication number
ATE233090T1
ATE233090T1 AT96930085T AT96930085T ATE233090T1 AT E233090 T1 ATE233090 T1 AT E233090T1 AT 96930085 T AT96930085 T AT 96930085T AT 96930085 T AT96930085 T AT 96930085T AT E233090 T1 ATE233090 T1 AT E233090T1
Authority
AT
Austria
Prior art keywords
pharmaceutical preparations
preparations containing
darifenacin
containing darifenacin
pharmaceutical
Prior art date
Application number
AT96930085T
Other languages
German (de)
English (en)
Inventor
Thomas Francis Dolan
Michael John Humphrey
Donald John Nichols
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10780813&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE233090(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Application granted granted Critical
Publication of ATE233090T1 publication Critical patent/ATE233090T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT96930085T 1995-09-15 1996-08-21 Darifenacin enthaltende pharmazeutische zubereitungen ATE233090T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9518953.6A GB9518953D0 (en) 1995-09-15 1995-09-15 Pharmaceutical formulations
PCT/EP1996/003719 WO1997009980A1 (en) 1995-09-15 1996-08-21 Pharmaceutical formulations containing darifenacin

Publications (1)

Publication Number Publication Date
ATE233090T1 true ATE233090T1 (de) 2003-03-15

Family

ID=10780813

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96930085T ATE233090T1 (de) 1995-09-15 1996-08-21 Darifenacin enthaltende pharmazeutische zubereitungen
AT02015165T ATE269076T1 (de) 1995-09-15 1996-08-21 Darifenacin enthaltende pharmazeutische zubereitungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02015165T ATE269076T1 (de) 1995-09-15 1996-08-21 Darifenacin enthaltende pharmazeutische zubereitungen

Country Status (32)

Country Link
US (1) US6106864A (enExample)
EP (2) EP1245231B1 (enExample)
JP (1) JP3403203B2 (enExample)
KR (1) KR100348585B1 (enExample)
CN (1) CN1303998C (enExample)
AR (1) AR005231A1 (enExample)
AT (2) ATE233090T1 (enExample)
BR (2) BR9610153A (enExample)
CA (1) CA2230314C (enExample)
CO (1) CO4750822A1 (enExample)
CY (3) CY2468B1 (enExample)
CZ (1) CZ294024B6 (enExample)
DE (4) DE69632753T2 (enExample)
DK (2) DK0850059T3 (enExample)
EG (1) EG23826A (enExample)
ES (2) ES2224002T3 (enExample)
FR (1) FR05C0019I2 (enExample)
GB (1) GB9518953D0 (enExample)
HU (2) HU227397B1 (enExample)
IL (1) IL122746A (enExample)
LU (1) LU91163I2 (enExample)
MY (1) MY125662A (enExample)
NL (1) NL300190I2 (enExample)
NO (2) NO314783B1 (enExample)
NZ (1) NZ316924A (enExample)
PL (1) PL185604B1 (enExample)
PT (1) PT1245231E (enExample)
RU (1) RU2163803C2 (enExample)
TR (1) TR199800461T1 (enExample)
TW (1) TW442300B (enExample)
WO (1) WO1997009980A1 (enExample)
ZA (1) ZA967745B (enExample)

Families Citing this family (314)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010029519A (ko) * 1996-09-19 2001-04-06 이곤 이 버그 요실금 치료 방법
US20100137358A1 (en) * 1996-11-05 2010-06-03 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US7858119B1 (en) * 2000-05-09 2010-12-28 Amina Odidi Extended release pharmaceuticals
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
DE10149674A1 (de) * 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US7163696B2 (en) * 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
GB0129962D0 (en) 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
BR0316572A (pt) 2002-12-13 2005-10-04 Warner Lambert Co Ligando alfa-2-delta para o tratamento de sintomas do trato variáveis inferior, utilização e produto deste
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
US20040235857A1 (en) * 2003-02-11 2004-11-25 Pfizer Inc Crystalline therapeutic agent
PA8597401A1 (es) * 2003-03-14 2005-05-24 Pfizer Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep
US20040186046A1 (en) * 2003-03-17 2004-09-23 Pfizer Inc Treatment of type 1 diabetes with PDE5 inhibitors
KR100824193B1 (ko) 2003-04-29 2008-04-21 화이자 인코포레이티드 고혈압 치료에 유용한5,7-디아미노피라졸로[4,3-ｄ]피리미딘
US7268147B2 (en) * 2003-05-15 2007-09-11 Pfizer Inc Compounds useful for the treatment of diseases
CA2529984C (en) 2003-06-26 2012-09-25 Isa Odidi Oral multi-functional pharmaceutical capsule preparations of proton pump inhibitors
US20050043300A1 (en) * 2003-08-14 2005-02-24 Pfizer Inc. Piperazine derivatives
GEP20084527B (en) * 2003-09-03 2008-11-10 Pfizer Benzimidazolone compounds having 5-ht4 receptor agonistic activity
ES2334673T3 (es) 2003-09-12 2010-03-15 Pfizer Inc. Combinaciones que comprenden ligandos alfa-2-delta e inhibidores de recaptacion de serotonina/noradrenalina.
ES2295924T3 (es) * 2003-10-03 2008-04-16 Pfizer, Inc. Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
US7572799B2 (en) * 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
GB0327323D0 (en) * 2003-11-24 2003-12-31 Pfizer Ltd Novel pharmaceuticals
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
GB0402491D0 (en) * 2004-02-04 2004-03-10 Pfizer Ltd Medicaments
US7629358B2 (en) * 2004-03-17 2009-12-08 Pfizer Inc Compounds useful for the treatment of diseases
EP1735284A1 (en) * 2004-03-18 2006-12-27 Pfizer Limited N-(1-arylpyrazol-4l)sulfonamides and their use as parasiticides
PL1730103T3 (pl) * 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
US20050215542A1 (en) * 2004-03-23 2005-09-29 Pfizer Inc Compounds for the treatment of diseases
US7538141B2 (en) * 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
CA2562251C (en) * 2004-04-07 2009-04-28 Pfizer Inc. Pyrazolo'4,3-d pyrimidines
US7737163B2 (en) * 2004-06-15 2010-06-15 Pfizer Inc. Benzimidazolone carboxylic acid derivatives
EA200801607A1 (ru) * 2004-06-15 2008-10-30 Пфайзер Инк. Производные бензимидазолонкарбоновой кислоты
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
EA012119B1 (ru) * 2004-08-12 2009-08-28 Пфайзер Инк. ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНСУЛЬФАНИЛА В КАЧЕСТВЕ ИНГИБИТОРОВ p38 MAP КИНАЗЫ
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
CN101023064B (zh) 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
EP1809607B1 (en) * 2004-11-02 2008-12-17 Pfizer, Inc. Sulfonyl benzimidazole derivatives
US20060111416A1 (en) * 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
WO2006097817A1 (en) 2005-03-17 2006-09-21 Pfizer Japan Inc. N- (n-sulfonylaminomethyl) cyclopropanecarboxamide derivatives useful for the treatment of pain
CA2602566A1 (en) * 2005-03-28 2006-10-05 Pfizer Inc. Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists
US20080146643A1 (en) * 2005-06-15 2008-06-19 Pfizer Limited Combination
US20070149464A1 (en) * 2005-06-15 2007-06-28 Pfizer Inc. Combination
EP1893581B1 (en) * 2005-06-15 2010-01-27 Pfizer Limited Substituted arylpyrazoles for use against parasitites
US20080176865A1 (en) * 2005-06-15 2008-07-24 Pfizer Limited Substituted arylpyrazoles
US7645786B2 (en) * 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
US20080269233A1 (en) * 2005-08-04 2008-10-30 Mark David Andrews Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds
CA2618103A1 (en) * 2005-08-10 2007-02-15 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2365161T3 (es) * 2005-09-02 2011-09-23 Theravida, Inc. Terapia para el tratamiento de la vejiga hiperactiva.
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
NL2000323C2 (nl) 2005-12-20 2007-11-20 Pfizer Ltd Pyrimidine-derivaten.
US20070141684A1 (en) 2005-12-21 2007-06-21 Pfizer Inc Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US20090062326A1 (en) * 2006-03-17 2009-03-05 Spindel Eliot R M3 muscarinic receptor antagonists for treatment of m3 muscarinic receptor-expressing tumors
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US20100256357A1 (en) * 2006-08-09 2010-10-07 Agouron Pharmaceuticals, Inc. Heterocycles useful as inhibitors of carbonic anhydrase
US8278355B2 (en) * 2006-09-12 2012-10-02 Therexcell Pharma Inc. Isovaline for treatment of pain
RU2412188C2 (ru) * 2006-09-21 2011-02-20 Раквалиа Фарма Инк. Производные бензимидазола в качестве селективных ингибиторов кислотной помпы
CA2666539A1 (en) 2006-10-23 2008-05-02 Pfizer Inc. Substituted phenylmethyl bicyclocarboxyamide compounds
RU2322998C1 (ru) * 2006-11-16 2008-04-27 Общество с ограниченной ответственностью "Березовый мир" Носитель лекарственных и диагностических средств
AU2008211613B2 (en) * 2007-02-02 2013-05-23 Pfizer Products Inc. Tricyclic compounds and their use as glucocorticoid receptor modulators
US20100216823A1 (en) * 2007-05-24 2010-08-26 Pfizer Inc. Spirocyclic Derivatives
CN101084891A (zh) * 2007-06-29 2007-12-12 北京本草天源药物研究院 一种用于口服的达非那新或其药用盐的药物制剂
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US8323695B2 (en) 2007-08-13 2012-12-04 Mcneil-Ppc, Inc. Method for stabilizing phenylephrine
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
US20110092564A1 (en) * 2008-02-26 2011-04-21 Ernest Puil Cyclic amino acids for the treatment of pain
CN102099033B (zh) * 2008-05-16 2012-10-24 阿克西斯股份有限公司 用于治疗纤维肌痛症的药物组合物
WO2009140078A1 (en) * 2008-05-16 2009-11-19 The Procter & Gamble Company Treatment of lower urinary tract dysfunction with cb2-receptor-selective agonists
ES2465478T3 (es) * 2008-05-30 2014-06-05 Ucb Pharma, S.A. Composiciones farmacéuticas que comprenden brivaracetam
US8518952B2 (en) * 2008-08-06 2013-08-27 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as CHK-1 inhibitors
EP2163253B1 (en) 2008-09-15 2013-07-17 ULLRICH, Oliver Extracts from the plant Hornstedtia scyphifera and immunosuppressive effects thereof
KR101637337B1 (ko) 2008-11-21 2016-07-07 라퀄리아 파마 인코포레이티드 5-ｈｔ2ｂ 수용체 길항활성을 가지는 신규 피라졸-3-카복사미드 유도체
CA2747419C (en) 2009-01-12 2014-07-08 Icagen, Inc. Sulfonamide derivatives
EP2406281B1 (en) 2009-03-12 2016-02-17 Haase Investments UG Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
EP2233502A1 (en) 2009-03-27 2010-09-29 Deutsches Rheuma-Forschungszentrum Berlin Sialylated antigen-specific antibodies for treatment or prophylaxis of unwanted inflammatory immune reactions and methods of producing them
EP2236516A1 (en) 2009-03-31 2010-10-06 Charité-Universitätsmedizin Berlin (Charité) Polypeptides and use thereof for treatment of traumatic or degenerative neuronal injury
CN102448978A (zh) 2009-05-29 2012-05-09 辉瑞有限公司 新颖的糖皮质激素受体激动剂
EP2266563A1 (en) 2009-06-11 2010-12-29 Charité-Universitätsmedizin Berlin (Charité) Use of opioid receptor antagonists for acute treatment of paraphilic arousal states
WO2011004276A1 (en) 2009-07-06 2011-01-13 Pfizer Limited Hepatitis c virus inhibitors
US8617763B2 (en) * 2009-08-12 2013-12-31 Bloom Energy Corporation Internal reforming anode for solid oxide fuel cells
EP2509978A1 (en) 2009-12-11 2012-10-17 E.I. Du Pont De Nemours And Company Azocyclic inhibitors of fatty acid amide hydrolase
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
RS54180B1 (sr) 2009-12-23 2015-12-31 Takeda Pharmaceutical Company Limited Fuzionisani heteroaromatski pirolidinoni kao syk inhibitori
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
WO2011154871A1 (en) 2010-06-10 2011-12-15 Pfizer Limited Hepatitis c virus inhibitors
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof
JP5860045B2 (ja) 2010-07-09 2016-02-16 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 化合物
ES2533065T3 (es) 2010-07-09 2015-04-07 Pfizer Limited Bencenosulfonamidas útiles como inhibidores de los canales de sodio
ES2532356T3 (es) 2010-07-09 2015-03-26 Pfizer Limited N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
ES2526981T3 (es) 2010-07-12 2015-01-19 Pfizer Limited N-sulfonilbenzamidas como inhibidores de canales de sodio dependientes de voltaje
CA2804877A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Sulfonamide derivatives as nav1.7 inhibitors for the treatment of pain
CA2804351A1 (en) 2010-07-12 2012-01-19 Pfizer Limited Chemical compounds
US9096500B2 (en) 2010-07-12 2015-08-04 Pfizer Limited Acyl sulfonamide compounds
JP2013532184A (ja) 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
AU2011330850B2 (en) 2010-11-15 2016-01-28 Viiv Healthcare Uk Limited Inhibitors of HIV replication
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
CN102048706B (zh) * 2011-01-12 2012-02-22 山东创新药物研发有限公司 一种氢溴酸达非那新缓释片及制备方法
WO2012095781A1 (en) 2011-01-13 2012-07-19 Pfizer Limited Indazole derivatives as sodium channel inhibitors
EP2489663A1 (en) 2011-02-16 2012-08-22 Almirall, S.A. Compounds as syk kinase inhibitors
ES2533042T3 (es) 2011-02-25 2015-04-07 Takeda Pharmaceutical Company Limited Oxazinopteridinas y oxazinopteridinonas N-sustituidas
WO2012120398A1 (en) 2011-03-04 2012-09-13 Pfizer Limited Aryl substituted carboxamide derivatives as trpm8 modulators
ES2581848T3 (es) 2011-04-05 2016-09-07 Pfizer Limited Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
EP2518071A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Imidazopyridine derivatives as PI3K inhibitors
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN103813792B (zh) 2011-05-10 2015-11-25 塞拉维达公司 用于治疗膀胱过度活动症的索利那新和唾液刺激剂的组合
WO2012154775A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder
CN103702995B (zh) 2011-05-18 2016-04-13 拉夸里亚创药株式会社 4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
BR112014002141A2 (pt) 2011-08-02 2017-02-21 Pfizer crizotinib para uso no tratamento de câncer
WO2013054185A1 (en) 2011-10-13 2013-04-18 Pfizer, Inc. Pyrimidine and pyridine derivatives useful in therapy
CA2851412A1 (en) 2011-10-19 2013-04-25 Zoetis Llc Use of aminoacetonitrile derivatives against endoparasites
JP5363636B2 (ja) 2011-10-21 2013-12-11 ファイザー・リミテッド 新規な塩および医学的使用
UA109220C2 (uk) 2011-10-26 2015-07-27 Пфайзер Лімітед Похідні (4-фенілімідазол-2-іл)етиламіну як модулятори натрієвих каналів
ES2648901T3 (es) 2011-10-28 2018-01-08 Inhibitaxin Limited Derivados de piridazina útiles en terapia
US9085517B2 (en) 2011-12-15 2015-07-21 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
CN102579379B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种药物缓释制剂及其制备方法
CN102600096B (zh) * 2011-12-29 2016-08-10 北京科信必成医药科技发展有限公司 一种达非那新缓释制剂及其制备方法
EP2800740A1 (en) 2012-01-04 2014-11-12 Pfizer Limited N-aminosulfonyl benzamides
ES2548228T3 (es) 2012-02-03 2015-10-15 Pfizer Inc Derivados de bencimidazol e imidazopiridina como moduladores de canal de sodio
KR101692600B1 (ko) 2012-03-06 2017-01-03 화이자 인코포레이티드 증식성 질환 치료용 거대환형 유도체
US9365566B2 (en) 2012-03-27 2016-06-14 Takeda Pharmaceutical Company Limited Cinnoline derivatives
US9353062B2 (en) 2012-04-04 2016-05-31 Hangzhouderenyucheng Biotechnology Ltd Substituted quinolines as bruton's tyrosine kinases inhibitors
UY34893A (es) 2012-07-10 2014-02-28 Takeda Pharmaceutical Derivados de azaindol
EP2909212B1 (en) 2012-09-07 2017-02-22 Takeda Pharmaceutical Company Limited Substituted 1,4-dihydropyrazolo[4,3-b]indoles
WO2014045029A1 (en) 2012-09-18 2014-03-27 Ziarco Pharma Ltd 2-(2-aminocyclohexyl)amino-pyrimidine-5-carboxamides as spleen tyrosine kinasei(syk) inhibitors
WO2014049488A1 (en) 2012-09-28 2014-04-03 Pfizer Inc. Benzamide and heterobenzamide compounds
CA2885259A1 (en) 2012-10-04 2014-04-10 Pfizer Limited Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
US20150250785A1 (en) 2012-10-04 2015-09-10 Pfizer Limited Tropomyosin-Related Kinase Inhibitors
US20150218172A1 (en) 2012-10-04 2015-08-06 Pfizer Limited Pyrrolo[2,3-D]Pyrimidine Tropomyosin-Related Kinase Inhibitors
WO2014060431A1 (en) 2012-10-16 2014-04-24 Almirall, S.A. Pyrrolotriazinone derivatives as pi3k inhibitors
EP2917216B1 (en) 2012-11-08 2017-10-18 Pfizer Inc Heteroaromatic compounds as dopamine d1 ligands
HK1210608A1 (en) 2012-11-08 2016-04-29 辉瑞大药厂 Heteroaromatic compounds and their use as dopamine d1 ligands
CA2890861C (en) 2012-11-21 2021-03-30 Raqualia Pharma Inc. Polymorphic forms of 4-{[4-({[4-(2,2,2-trifluoroethoxy)-1,2-benzisoxazol-3-yl]oxy}methyl)piperidin-1-yl]methyl}-tetrahydro-2h-pyran-4-carboxylic acid
AP2015008444A0 (en) 2012-12-03 2015-05-31 Pfizer Novel selective androgen receptor modulators
UA112028C2 (uk) 2012-12-14 2016-07-11 Пфайзер Лімітед Похідні імідазопіридазину як модулятори гамка-рецептора
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
AR094797A1 (es) 2013-02-15 2015-08-26 Almirall Sa Derivados de pirrolotriazina como inhibidores de pi3k
PL3431475T3 (pl) 2013-02-21 2021-09-13 Pfizer Inc. Stałe postacie selektywnego inhibitora CDK4/6
JO3377B1 (ar) 2013-03-11 2019-03-13 Takeda Pharmaceuticals Co مشتقات بيريدينيل وبيريدينيل مندمج
WO2014140159A1 (en) * 2013-03-13 2014-09-18 Ratiopharm Gmbh Dosage form comprising crizotinib
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
EP2792360A1 (en) 2013-04-18 2014-10-22 IP Gesellschaft für Management mbH (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
TW201443025A (zh) 2013-04-19 2014-11-16 Pfizer Ltd 化學化合物
WO2014181213A1 (en) 2013-05-10 2014-11-13 Pfizer Inc. Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
EP2997084A4 (en) 2013-05-17 2016-10-12 Acupac Packaging Inc WATER-FREE HYDROGELIC COMPOSITION
PT3013813T (pt) 2013-06-27 2019-06-14 Pfizer Compostos heteroaromáticos e a sua utilização como ligandos de d1 de dopamina
CN104513253A (zh) 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
WO2015092614A1 (en) 2013-12-20 2015-06-25 Pfizer Inc. Activating notch alterations in breast cancer
WO2015092610A1 (en) 2013-12-20 2015-06-25 Pfizer Limited N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2015106014A1 (en) 2014-01-09 2015-07-16 Takeda Pharmaceutical Company Limited Azaindole derivatives
UY35945A (es) 2014-01-09 2015-08-31 Takeda Pharmaceutical Derivados de azaindol
US20170197939A1 (en) 2014-04-15 2017-07-13 Pfizer Inc. Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
MD20160109A2 (ro) 2014-04-25 2017-04-30 Pfizer Inc. Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1
AP2016009464A0 (en) 2014-04-25 2016-09-30 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
CA2946990A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heterocyclic compounds and their use as dopamine d1 ligands
WO2015166370A1 (en) 2014-04-28 2015-11-05 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
EP3140298A1 (en) 2014-05-07 2017-03-15 Pfizer Inc. Tropomyosin-related kinase inhibitors
EA201650029A1 (ru) 2014-05-14 2017-09-29 Пфайзер Инк. Пиразолопиридины и пиразолопиримидины
SI3143019T1 (sl) 2014-05-15 2021-03-31 Pfizer Inc. Kristalna oblika 6-((4R)-4-metil-1,2-dioksido-1,2,6-tiadiazinan-2-IL)isokvinolin-1- karbonitrila
JP6572414B2 (ja) 2014-05-20 2019-09-11 ラクオリア創薬株式会社 ベンズイソオキサゾール誘導体塩
US10328082B2 (en) 2014-05-30 2019-06-25 Pfizer Inc. Methods of use and combinations
EP3148992A1 (en) 2014-05-30 2017-04-05 Pfizer Inc. Benzenesulfonamides useful as sodium channel inhibitors
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
EP3157915B1 (en) 2014-06-17 2019-02-27 Pfizer Inc Substituted dihydroisoquinolinone compounds
WO2015193768A1 (en) 2014-06-17 2015-12-23 Pfizer Inc. Aryl fused lactams as ezh2 modulators
WO2016009296A1 (en) 2014-07-16 2016-01-21 Pfizer Inc. N-acylpiperidine ether tropomyosin-related kinase inhibitors
WO2016009303A1 (en) 2014-07-17 2016-01-21 Pfizer Inc. Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
WO2016009297A1 (en) 2014-07-18 2016-01-21 Pfizer Inc. Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
WO2016020784A1 (en) 2014-08-05 2016-02-11 Pfizer Inc. N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
WO2016034971A1 (en) 2014-09-04 2016-03-10 Pfizer Limited Sulfonamides derivatives as urat1 inhibitors
US10017529B2 (en) 2014-09-16 2018-07-10 BioPharma Works LLC Metformin derivatives
GB201417163D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
GB201417165D0 (en) 2014-09-29 2014-11-12 Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin Treatments for Autoimmune Disease
WO2016067143A1 (en) 2014-10-28 2016-05-06 Pfizer Inc. N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
ES2746839T3 (es) 2014-12-18 2020-03-09 Pfizer Derivados de pirimidina y triazina y su uso como inhibidores de AXL
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
EP3556376A1 (en) 2015-01-22 2019-10-23 Phytoplant Research S.L. Methods of purifying cannabinoids, compositions and kits thereof
ES2792899T3 (es) 2015-02-24 2020-11-12 Pfizer Derivados de nucleósidos sustituidos útiles como agentes anticancerosos
EP3268046A4 (en) 2015-03-13 2018-11-21 Endocyte, Inc. Conjugates for treating diseases
US10214509B2 (en) 2015-04-21 2019-02-26 Almirall, S.A. Amino-substituted heterocyclic derivatives as sodium channel inhibitors
PT3302565T (pt) 2015-06-04 2020-01-14 Pfizer Formas de dosagem sólida de palbociclib
ES2823049T3 (es) 2015-07-31 2021-05-05 Pfizer Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-ilo y derivados de carbamato de 1,1,1-trifluoro-4-hidroxibutan-2-ilo como inhibidores de MAGL
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
JP2018536677A (ja) 2015-12-10 2018-12-13 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ てんかんおよび疼痛の治療において使用するための、ＧＡＢＡ受容体モジュレーターとしての式（Ｉ）の４−（ビフェン−３−イル）−１Ｈ−ピラゾロ［３，４−ｃ］ピリダジン誘導体
CA3009610C (en) 2015-12-24 2024-02-13 Takeda Pharmaceutical Company Limited Cocrystal of (s)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1h-1,2,4-triazol-5(4h)-one, production method thereof and pharmaceutical composition containing said cocrystal
KR20180105161A (ko) 2016-01-07 2018-09-27 씨에스 파마테크 리미티드 Egfr 티로신 키나제의 임상적으로 중요한 돌연변이체의 선택적 억제제
WO2017119732A1 (en) 2016-01-08 2017-07-13 Samsung Electronics Co., Ltd. Electronic device and operating method thereof
JP6929857B2 (ja) 2016-01-15 2021-09-01 ファイザー・インク ６，７，８，９−テトラヒドロ−５Ｈ−ピリド［２，３−ｄ］アゼピンドーパミンＤ３リガンド
MX394356B (es) 2016-01-20 2025-03-24 Theravida Inc Métodos y composiciones para tratar hiperhidrosis.
WO2017156341A1 (en) 2016-03-09 2017-09-14 Beijing Percans Oncology Co. Ltd. Tumor cell suspension cultures and related methods
ES2886080T3 (es) 2016-03-31 2021-12-16 Takeda Pharmaceuticals Co Complejos de isoquinolinil triazolona
CA2969295A1 (en) 2016-06-06 2017-12-06 Pfizer Inc. Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
EP3496724B8 (en) 2016-08-12 2021-11-17 Madera Therapeutics, LLC Protein kinase regulators
CN109803968A (zh) 2016-08-15 2019-05-24 辉瑞公司 吡啶并嘧啶酮cdk2/4/6抑制剂
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
WO2018118782A2 (en) 2016-12-20 2018-06-28 Oligomerix, Inc. Novel benzofuran, benzothiophene, and indole analogs that inhibit the formation of tau oligomers and their method of use
EP3558950B1 (en) 2016-12-20 2023-05-10 Oligomerix, Inc. Novel quinazolinones that inhibit the formation of tau oligomers and their method of use
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
KR20190097242A (ko) 2017-01-23 2019-08-20 화이자 인코포레이티드 Magl 억제제로서의 헤테로시클릭 스피로 화합물
RU2732568C1 (ru) 2017-01-24 2020-09-21 Пфайзер Инк. Производные калихеамицина и их конъюгаты "антитело-лекарственное средство"
EP3600312B1 (en) 2017-03-26 2023-05-17 Takeda Pharmaceutical Company Limited Piperidinyl- and piperazinyl-substituted heteroaromatic carboxamides as modulators of gpr6
JOP20180057A1 (ar) 2017-06-15 2019-01-30 Takeda Pharmaceuticals Co مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
CN111132972B (zh) 2017-06-22 2024-07-12 克拉德夫制药有限公司 人sting的小分子调节剂
AU2018323053A1 (en) 2017-08-30 2020-03-19 Beijing Xuanyi Pharmasciences Co., Ltd Cyclic di-nucleotides as stimulator of interferon genes modulators
CN118684652A (zh) 2017-09-11 2024-09-24 克鲁松制药公司 SHP2的八氢环戊二烯并[c]吡咯别构抑制剂
TW201920108A (zh) 2017-09-25 2019-06-01 日商武田藥品工業有限公司 N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
KR20200088386A (ko) 2017-11-14 2020-07-22 화이자 인코포레이티드 Ezh2 억제제 병용 요법
CA3089490A1 (en) 2018-01-29 2019-08-01 Phytoplant Research S.L Methods of purifying cannabinoids using liquid:liquid chromatography
TW201942115A (zh) 2018-02-01 2019-11-01 美商輝瑞股份有限公司 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
TW201942116A (zh) 2018-02-09 2019-11-01 美商輝瑞股份有限公司 作為抗癌劑之四氫喹唑啉衍生物
WO2019166928A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
TWI834637B (zh) 2018-03-01 2024-03-11 日商武田藥品工業有限公司 六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
EP3784664B1 (en) 2018-04-26 2025-02-19 Pfizer Inc. 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
WO2019243823A1 (en) 2018-06-21 2019-12-26 Curadev Pharma Limited Azaheterocyclic small molecule modulators of human sting
CA3106510A1 (en) 2018-07-19 2020-01-23 Pfizer Inc. Heterocyclic spiro compounds as magl inhibitors
WO2020076728A1 (en) 2018-10-08 2020-04-16 Takeda Pharmaceutical Company Limited SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
US11142525B2 (en) 2018-11-15 2021-10-12 Pfizer Inc. Azalactam compounds as HPK1 inhibitors
AU2020211789A1 (en) 2019-01-23 2021-07-22 Pfizer Inc. Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
EP3917913A2 (en) 2019-01-31 2021-12-08 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
AU2020228047B2 (en) 2019-02-27 2025-11-20 Madera Therapeutics, LLC Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
WO2020198053A1 (en) 2019-03-22 2020-10-01 Takeda Pharmaceutical Company Limited 2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
MA55804A (fr) 2019-04-29 2022-04-06 Solent Therapeutics Llc Dérivés de 1,1-dioxyde de 3-amino-4h-benzo[e][1,2,4]thiadiazine en tant qu'inhibiteurs de mrgx2
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
EP4003961A2 (en) 2019-07-25 2022-06-01 Curadev Pharma Pvt. Ltd. Small molecule inhibitors of acetyl coenzyme a synthetase short chain 2 (acss2)
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
PH12022550597A1 (en) 2019-09-16 2024-03-04 Takeda Pharmaceuticals Co Azole-fused pyridazin-3(2h)-one derivatives
CA3166358A1 (en) 2020-02-12 2021-08-19 Monali BANERJEE Small molecule sting antagonists
TW202146017A (zh) 2020-03-05 2021-12-16 美商輝瑞股份有限公司 間變性淋巴瘤激酶抑制劑及周期蛋白依賴型激酶抑制劑之組合
AR121683A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
AR121682A1 (es) 2020-03-31 2022-06-29 Takeda Pharmaceuticals Co Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
BR112022020058A2 (pt) 2020-04-08 2022-11-22 Mission Therapeutics Ltd N-cianopirrolidinas com atividade como inibidores de usp30
CR20220548A (es) 2020-05-01 2022-12-12 Pfizer Compuestos de azalactama como inhibidores de hpk1
AU2021266690A1 (en) 2020-05-04 2022-11-10 Takeda Pharmaceutical Company Limited Luminally-acting N-(piperidin-4-yl)benzamide derivatives
WO2021224818A1 (en) 2020-05-08 2021-11-11 Pfizer Inc. Isoindolone compounds as hpk1 inhibitors
JP2023527025A (ja) 2020-05-28 2023-06-26 ミッション セラピューティクス リミティド ミトコンドリア機能不全の治療のためのｕｓｐ３０阻害剤としてのｎ－（１－シアノ－ピロリジン－３－イル）－５－（３－（トリフルオロメチル）フェニル）オキサゾール－２－カルボキサミド誘導体及び対応するオキサジアゾール誘導体
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
PL4161929T3 (pl) 2020-06-08 2026-01-05 Mission Therapeutics Limited 1-(5-(2-cyjanopirydyn-4-ylo)oksazolo-2-karbonylo)-4-metyloheksahydropirolo[3,4-b]pirolo-5(1h)-karbonitryl jako inhibitor usp30 do zastosowania w leczeniu dysfunkcji mitochondriów, nowotworu i zwłóknienia
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
WO2022013692A1 (en) 2020-07-15 2022-01-20 Pfizer Inc. Polymorphs of (1s,2s,3s,5r)-3-((6-(difluoromethyl)-5-flu­oro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7h-pyrrolo[2,3-d]­pyrimidin-7-yl)cyclopentane-1,2-diol mono-hydrochloride
US20240116937A1 (en) 2020-07-15 2024-04-11 Pfizer Inc. Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
CA3189632A1 (en) 2020-07-20 2022-01-27 Pfizer Inc. Combination therapy
WO2022018667A1 (en) 2020-07-24 2022-01-27 Pfizer Inc. Combination therapies using cdk2 and cdc25a inhibitors
GB202011811D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
GB202011812D0 (en) 2020-07-29 2020-09-09 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds
CN116322693A (zh) 2020-08-13 2023-06-23 辉瑞公司 组合疗法
JP7260606B2 (ja) 2020-09-15 2023-04-18 ファイザー・インク 固体形態のｃｄｋ４阻害薬
TW202229239A (zh) 2020-09-23 2022-08-01 日商武田藥品工業股份有限公司 作為ｒｉｐｋ２抑制劑之３－（６－胺基吡啶－３－基）苯甲醯胺衍生物
WO2022077034A1 (en) 2020-10-09 2022-04-14 Napa Therapeutics Ltd. Heteroaryl amide inhibitors of cd38
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
AU2021405409A1 (en) 2020-12-22 2023-07-06 Effector Therapeutics, Inc. Solid forms of an eif4e inhibitor
EP4267563A1 (en) 2020-12-24 2023-11-01 Pfizer Inc. Solid forms of a cdk2 inhibitor
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
KR20230159510A (ko) 2021-03-24 2023-11-21 화이자 인코포레이티드 Ddr 유전자 돌연변이된 전이성 거세-감수성 전립선암의 치료를 위한 탈라조파립과 항안드로겐의 조합
GB202104609D0 (en) 2021-03-31 2021-05-12 Sevenless Therapeutics Ltd New Treatments for Pain
AU2022250712A1 (en) 2021-03-31 2023-10-05 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
JP2024516359A (ja) 2021-04-07 2024-04-15 ライフアーク Ｕｌｋ１／２阻害剤およびその使用
WO2022229846A1 (en) 2021-04-29 2022-11-03 Pfizer Inc. Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
IL309252A (en) 2021-06-26 2024-02-01 Array Biopharma Inc Inhibitors of HER2 mutations
WO2023002362A1 (en) 2021-07-22 2023-01-26 Pfizer Inc. Treatment of hematological malignancy
IL310679A (en) 2021-08-11 2024-04-01 Curadev Pharma Pvt Ltd Urea history of small molecules as STING antagonists
CA3228528A1 (en) 2021-08-11 2023-02-16 Monali BANERJEE Small molecule sting antagonists
WO2023084459A1 (en) 2021-11-15 2023-05-19 Pfizer Inc. Methods of treating sars-cov-2
EP4441052B1 (en) 2021-12-01 2025-11-19 Fundación del Sector Público Estatal Centro Nacional de Investigaciones Oncológicas Carlos III (F.S.P. CNIO) Compounds
US20250034122A1 (en) 2021-12-01 2025-01-30 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors
IL312980A (en) 2021-12-02 2024-07-01 Pfizer Methods and dosing regimens comprising a cdk2 inhibitor and a cdk4 inhibitor for treating cancer
IL315998A (en) 2022-03-30 2024-11-01 Takeda Pharmaceuticals Co N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
AR129012A1 (es) 2022-04-07 2024-07-03 Takeda Pharmaceuticals Co Derivados de piridazina fusionados
EP4554674A1 (en) 2022-07-15 2025-05-21 Jazz Pharmaceuticals Ireland Limited Biaryl ether urea compounds as faah inhibitors
EP4562017A1 (en) 2022-07-29 2025-06-04 Pfizer Inc. Novel acc inhibitors
WO2024033845A1 (en) 2022-08-10 2024-02-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP4568662A1 (en) 2022-08-11 2025-06-18 Evexta Bio Compounds for treating cancer
WO2024074827A1 (en) 2022-10-05 2024-04-11 Sevenless Therapeutics Limited New treatments for pain
TW202434599A (zh) 2022-11-15 2024-09-01 英商克拉德夫製藥有限公司 造血前驅細胞激酶1之吡啶酮及嘧啶酮抑制劑
IL321429A (en) 2023-01-13 2025-08-01 Neurim Pharmaceuticals 1991 Ltd Piromelatine for treating parasomnias associated with loss of rem sleep atonia
EP4655303A1 (en) 2023-01-26 2025-12-03 Takeda Pharmaceutical Company Limited 1-amino-4-phenylphthalazine derivatives useful for the treatment of neurodegenerative diseases
TW202506678A (zh) 2023-04-14 2025-02-16 日商武田藥品工業股份有限公司 雜環化合物
WO2024251978A1 (en) 2023-06-09 2024-12-12 Institut Gustave Roussy Drug conjugate targeting ctla4, products comprising the same and therapeutic uses thereof
TW202500155A (zh) 2023-06-12 2025-01-01 美商亞文納營運公司 雌激素受體降解劑之固體口服劑型
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
US20250057848A1 (en) 2023-08-14 2025-02-20 Neurim Pharmaceuticals (1991) Ltd. Gal475 compositions and methods of use thereof
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
WO2025074305A1 (en) 2023-10-04 2025-04-10 Takeda Pharmaceutical Company Limited N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
GB202319181D0 (en) 2023-12-14 2024-01-31 Imperial College Innovations Ltd Nora Inhibitors
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025168601A1 (en) 2024-02-05 2025-08-14 Evexta Bio Quinazoline carboxamide azetidine compounds for use in treating hormone dependent diseases
WO2025229624A2 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited New cd38 inhibitors
WO2025231370A1 (en) 2024-05-02 2025-11-06 Napa Therapeutics Limited Inhibitors of cd38
WO2025233837A1 (en) 2024-05-07 2025-11-13 Takeda Pharmaceutical Company Limited 4h-pyrimido[1,2-a]pyrimidin-4-one derivatives for use as nlrp3 inflammasome inhibitors for the treatment of neurodegenerative disorder
WO2025247951A1 (en) 2024-05-28 2025-12-04 Institut Gustave Roussy Fyn kinase inhibitors, combinations and uses thereof
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906166D0 (en) * 1989-03-17 1989-05-04 Pfizer Ltd Therapeutic agents
US5233053A (en) * 1989-03-17 1993-08-03 Pfizer Inc. Pyrrolidine derivatives
PT93637A (pt) * 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness

Also Published As

Publication number Publication date
NO981073L (no) 1998-03-11
FR05C0019I2 (enExample) 2005-11-04
KR100348585B1 (ko) 2002-10-31
IL122746A0 (en) 1998-08-16
DE69626397T2 (de) 2003-07-17
EP1245231A2 (en) 2002-10-02
ES2188782T3 (es) 2003-07-01
HU227397B1 (en) 2011-05-30
CN1303998C (zh) 2007-03-14
ES2224002T3 (es) 2005-03-01
BR122012014331B1 (pt) 2019-10-08
EP1245231A3 (en) 2003-01-15
GB9518953D0 (en) 1995-11-15
IL122746A (en) 2000-12-06
ATE269076T1 (de) 2004-07-15
CY2468B1 (en) 2005-06-03
ZA967745B (en) 1998-03-13
CY2005007I2 (el) 2009-11-04
WO1997009980A1 (en) 1997-03-20
CY2005007I1 (el) 2009-11-04
CA2230314A1 (en) 1997-03-20
NO981073D0 (no) 1998-03-11
LU91163I2 (fr) 2005-06-20
RU2163803C2 (ru) 2001-03-10
MX9802026A (es) 1998-08-30
NO2005009I2 (no) 2006-11-27
BR122012014331B8 (pt) 2021-05-25
PL325598A1 (en) 1998-08-03
NL300190I2 (nl) 2005-08-01
HUP9802339A2 (hu) 1999-08-30
AU703866B2 (en) 1999-04-01
DE122005000024I2 (de) 2006-11-23
FR05C0019I1 (enExample) 2005-05-27
HU0500976D0 (en) 2005-12-28
DK0850059T3 (da) 2003-03-31
EP0850059B1 (en) 2003-02-26
DE69632753T2 (de) 2005-07-14
DE69632753D1 (de) 2004-07-22
NZ316924A (en) 1999-06-29
BR9610153A (pt) 1999-01-05
CZ294024B6 (cs) 2004-09-15
PL185604B1 (pl) 2003-06-30
EP0850059A1 (en) 1998-07-01
EP1245231B1 (en) 2004-06-16
HU225236B1 (en) 2006-08-28
DK1245231T3 (da) 2004-10-25
BR122012014331A8 (pt) 2018-07-31
US6106864A (en) 2000-08-22
AR005231A1 (es) 1999-04-28
CA2230314C (en) 2003-06-24
MY125662A (en) 2006-08-30
KR19990044653A (ko) 1999-06-25
NL300190I1 (nl) 2005-07-01
DE122005000024I1 (de) 2005-08-04
CO4750822A1 (es) 1999-03-31
TW442300B (en) 2001-06-23
AU6927596A (en) 1997-04-01
EG23826A (en) 2007-09-25
CN1195984A (zh) 1998-10-14
HUP9802339A3 (en) 1999-09-28
CY2585B2 (en) 2009-11-04
JP3403203B2 (ja) 2003-05-06
BR122012014331A2 (enExample) 1999-01-05
PT1245231E (pt) 2004-10-29
DE69626397D1 (de) 2003-04-03
TR199800461T1 (xx) 1998-05-21
NO314783B1 (no) 2003-05-26
NO2005009I1 (no) 2005-04-18
CZ73298A3 (cs) 1999-03-17
JPH10511112A (ja) 1998-10-27

Similar Documents

Publication Publication Date Title
DE69632753D1 (de) Darifenacin enthaltende pharmazeutische Zubereitungen
DE69814091D1 (de) Voriconazol-enthaltende pharmazeutische zubereitungen
DE69525148D1 (de) Pharmazeutische formulierung
NO954146D0 (no) Belagte farmasöytiske preparater
BR9611626A (pt) Formulações farmacéuticas
IL139235A0 (en) Pharmaceutical preparations
FI973243L (fi) Uusi farmaseuttinen yhdistelmä
DE69831620D1 (de) Arzneizubereitungen enthaltend Kannabinoide
DE69629755D1 (de) Irbesartanhaltiges Arzneimittel
ATE288419T1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
NO981008D0 (no) Farmasöytisk formulering
DE4294862T1 (de) Pharmazeutische Komposition
DE69614407D1 (de) Pharmazeutische zusammensetzungen
EE9800275A (et) Misolastiini sisaldavad prolongeeritud toimega farmatseutilised preparaadid
ATE269695T1 (de) Pharmazeutische pellets
FI973230L (fi) Uusi farmaseuttinen formulaatio
FI951155L (fi) Farmaseuttinen valmiste
DE59610423D1 (de) Partikulare arzneiform
DE19681529D2 (de) Pharmazeutische Darreichungsform
IL119208A0 (en) Pharmaceutical preparations containing ketoprofen
ATA77096A (de) Pharmazeutische präparation
SE9302429D0 (sv) New pharmaceutical preparation ii
NO920039L (no) Farmasoeytiske preparater
UA1292S (uk) Таблетка фармацевтична